The announcement
https://www.fda.gov/News
Events/Newsroom
/PressAnnouncements/
ucm635157.htm comes at a time when the regulator
is aiming to curb the surge in teenage use of the popular nicotine
devices, which the FDA Commissioner Scott Gottlieb, due to leave the
agency this month, has termed as an "epidemic".
The agency said it had observed a slight increase in the reports of
seizures since last June and has identified 35 cases of seizures
following use of e-cigarettes between 2010 and early 2019. The
seizures, which mostly involved youth or young adult users, had
occurred after a few puffs or up to one day after use.
E-cigarettes have been a divisive topic in the public health
community, with some focusing on the benefit of shifting smokers to
less harmful nicotine products, while others fear it would create a
new generation addicted to nicotine.
Seizures or convulsions are known potential side effects of nicotine
poisoning and have been reported in relation to intentional or
accidental swallowing of nicotine-containing e-liquids, according to
the FDA statement.
However, the agency said it could not yet say for certain that
e-cigarettes had caused the seizures and the cases warrant an
investigation into whether there is in fact a connection.
[to top of second column] |
Last month, the FDA had released formal plans to curb the sale of
flavored e-cigarettes, which involve restricting the availability of
flavors other than tobacco, mint and menthol, to stores or online
portals where strong age-verification protocols are in place.
The agency on Wednesday said that it was also looking into any
additional consequences to nicotine use as some e-cigarettes deliver
high concentrations of nicotine.
The FDA said many of the reports it had received lacked enough
information to identify a specific brand or sub-brand of
e-cigarettes.
Some of the reported seizure cases involved users who had a prior
history of seizure diagnosis, while a few others suffered seizures
in association with use of other substances such as marijuana or
amphetamines.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shailesh
Kuber)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |